Artivion to Participate in Upcoming Investor Conferences

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.

https://mma.prnewswire.com/media/1728034/Artivion_new_Logo.jpg

Artivion's management team will present at the upcomingCanaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 10:30 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.

Artivion management will also be participating in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference on Tuesday, August 12, 2025. Due to the format of this event no webcast will be available.

About Artivion, Inc. Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Contact:

Artivion Gilmartin Group LLCLance A. Berry Brian Johnston / Laine MorganExecutive Vice President & Phone: 332-895-3222Chief Financial Officer investors@artivion.comPhone: 770-419-3355

https://c212.net/c/img/favicon.png?sn=CL41012&sd=2025-07-30

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-upcoming-investor-conferences-302517744.html

SOURCE Artivion, Inc.

https://rt.newswire.ca/rt.gif?NewsItemId=CL41012&Transmission_Id=202507301610PR_NEWS_USPR_____CL41012&DateId=20250730

Scroll to Top